Ustekinumab as induction and maintenance therapy for ulcerative colitis – national extended follow-up and a review of the literatureJD Chetwood, Rupert W. Leong, Suneel Gupta et al.|Expert Opinion on Drug Safety|2023Cited by 3
Australian Real‐World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Results of the <scp>AURORA</scp> Study, Including the <scp>ANZIBD</scp> ConsortiumYoon‐Kyo An, Jakob Begun, Natalie Allan et al.|JGH Open|2025Cited by 1
P663 Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn’s disease patients: results from the AURORA Study including ANZIBDC CohortYoon‐Kyo An, Jakob Begun, Niamh Lindsay et al.|Journal of Crohn s and Colitis|2023Cited by 0
Tu1749 POST-USTEKINUMAB INDUCTION IL-12, IL-23, AND USTEKINUMAB LEVELS ARE ASSOCIATED WITH CLINICAL RESPONSE IN A MULTICENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDYYoon‐Kyo An, Jakob Begun, Niamh Lindsay et al.|Gastroenterology|2023Cited by 0
Su1733 BASELINE CYTOKINE LEVELS AND MICROBIOME SIGNATURES ARE ASSOCITED WITH CLINICAL RESPONSE FOLLOWING USTEKINUMAB INDUCTION IN A MULTI-CENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDYYoon‐Kyo An, Jakob Begun, Niamh Lindsay et al.|Gastroenterology|2023Cited by 0